四项覆性技术落地罗湖！中欧医药中心解码“未来医疗”新范式

Core Viewpoint - The establishment of the China-Europe Innovation Pharmaceutical and Health Research Center is reshaping the future of healthcare through disruptive technologies, focusing on innovative solutions in the Guangdong-Hong Kong-Macao Greater Bay Area [1][15]. Group 1: Disruptive Technologies - The center is home to leading researchers in the field of biomedicine, including Lei Xiaohua, Ruan Changshun, and Li Hongchang, who are pioneering groundbreaking technologies [1][15]. - Lei Xiaohua's team has achieved a world-first in the automated 3D growth and long-term cryopreservation of human pluripotent stem cells in a microgravity environment, marking a significant advancement in space life sciences [3][5]. - Ruan Changshun has developed a series of functional bioprinting materials, enabling precise control over mechanical properties and degradation rates for bone defect repair [5][7]. - Li Hongchang's research in targeted protein degradation offers a new broad-spectrum strategy for cancer treatment, utilizing autophagy-inducing antibodies to effectively degrade membrane proteins [9][11]. Group 2: Innovative Enterprises - Xunliao Technology (Shenzhen) is an innovative company incubated by the center, leveraging AI-driven platforms to support the development and application of advanced therapy medicinal products (ATMPs) [12][14]. - The company aims to revolutionize the biopharmaceutical industry by reducing R&D cycles from years to months and transitioning from experience-driven production to data-driven manufacturing [14]. Group 3: Center's Role and Structure - The China-Europe Medical Center serves as a hub for disruptive technology incubation, focusing on advanced therapy drugs, digital health, and longevity medicine [15][18]. - The center has established a comprehensive support system, including a GMP-grade cell production center and a synthetic micro-ecology platform, facilitating the transition from basic research to clinical applications [20]. - Collaborations with leading pharmaceutical companies and the establishment of a commercial ecosystem are driving the rapid industrialization of innovative technologies [20].